Latest From David Wild
In the United States, where Black inequity has become a focus of diversity efforts, biopharma companies are working hard to recruit and retain individuals from these communities. In fact, the search for such employees and leaders has become so competitive that competition for diverse talent within the industry is now "fierce," as one executive told In Vivo.
In this episode of the In Vivo podcast, David Wild speaks with Petra Jantzer, senior managing director and global life sciences lead at Accenture, about the changing deals landscape. The discussion centers on the shifts in M&A strategies that Jantzer has been seeing among big pharmas and the need for other companies to adapt to a world in which technologies and processes become a key focus of growth.
While artificial intelligence has proven its value in drug discovery, for most companies, the power of their AI systems is only as strong as the data those systems are trained on. However, stakeholders – from individual companies to consortiums and service vendors -- are finding creative approaches to overcome the so-called data problem and strengthen their AI models.
Sweden is a European leader in the life sciences and now has its sights set on becoming a global force in digital and e-health. A rich academic tradition, strong manufacturing infrastructure and health care as a pillar of its unique Mixed Economy make Sweden an attractive home for pharma, biotech and medtech companies and a target for investors.
With over 300 members involved in all aspects of the life sciences, SwedenBIO's ongoing mission is to make the country’s sector as visible as possible while ensuring each member's interests are being met. The non-profit recently welcomed Frida Lawenius as its Director General and, in a Q&A, she told In Vivo that one of the most pressing challenges facing the sector is recruiting the talent needed to keep up with its growth.
Hype around the metaverse has made it a sexy topic, but a recent Accenture report grounds the concept in a sober, yet still exciting, reality. The consulting firm looked at how the metaverse is being applied in the life sciences sector and concluded that while it is early days and the concept remains nebulous, executives would be remiss if they ignored the growing possibilities the metaverse has to offer.